Related Experiment Videos
Group B streptococcus: prevention of early-onset neonatal sepsis
Julie S Platt1, William F O'Brien
1Division of Obstetrics and Maternal Fetal Medicine, College of Medicine, University of South Florida, Tampa, Florida, USA. mdpjsp@earthlink.net
Insights
Culture-based screening for Group B Streptococcus (GBS) is more effective in preventing neonatal GBS disease than risk-based strategies. Updated guidelines now recommend culture-based prevention for maternal carriers.
Area of Science:
- Neonatal infectious diseases
- Bacterial pathogenesis
- Public health strategies
Background:
- Group B Streptococcus (GBS) emerged as a significant neonatal pathogen in the 1970s.
- GBS neonatal disease has a high case-fatality rate (5-20%), making prevention a critical concern.
- Initial preventive guidelines from CDC and ACOG in 1996 showed reduced incidence but variable practice patterns.
Purpose of the Study:
- To analyze the effectiveness of different GBS prevention strategies.
- To outline current recommendations for maternal GBS therapy.
- To provide an understanding of GBS pathogen, colonization, transmission, and detection methods.
Main Methods:
- Comparative analysis of risk-based versus culture-based GBS prevention strategies.
- Review of historical GBS incidence data (1993-1999).
- Evaluation of CDC and ACOG guidelines and their impact on GBS disease reduction.
Main Results:
- Culture-based GBS prevention significantly reduces early-onset neonatal disease compared to risk-based protocols.
- Incidence of GBS-newborn disease decreased from 1.7 to 0.4 per 1,000 live births (1993-1999) with implemented strategies.
- CDC 2002 guidelines officially replaced risk-based strategies with culture-based GBS prevention.
Conclusions:
- Culture-based prevention is the superior strategy for reducing neonatal GBS disease.
- Intrapartum treatment of maternal GBS carriers is essential in the absence of a GBS vaccine.
- Ongoing research into GBS pathogen, detection, and maternal therapy is crucial for eradication efforts.
Unlabelled:
Group B streptococcus (GBS) was recognized as a major pathogen of neonatal disease in the 1970s. With a case-fatality rate of 5% to 20%, prevention of GBS neonatal disease has been an ongoing concern. The Centers for Disease Control and Prevention (CDC), and American College of Obstetricians and Gynecologists (ACOG) published guidelines for preventive strategies in 1996. These strategies, either a risk-based or a culture-based program, have been responsible for reduced incidence of GBS-newborn disease from 1.7 to 0.4 per 1,000 live births in the years 1993 to 1999. However, there has been considerable variability in practice patterns. Reanalysis now shows that a culture-based prevention strategy provides greater reduction in early-onset neonatal disease than a risk-based protocol. The CDC replacement guidelines of August 2002 recommend culture-based GBS prevention; the risk-based strategy is no longer supported. Continued efforts to eradicate GBS-newborn disease require an understanding of the pathogen, colonization, and transmission, GBS sampling and detection methods, and maternal therapy. Until a reliable vaccination against GBS is developed, prevention of neonatal GBS disease will rely upon intrapartum treatment of maternal carriers.
Target Audience:
Obstetricians & Gynecologists, Family Physicians
Learning Objectives:
After completion of this article, the reader will be able to define the pathogen, describe the methods of transmission and detection, and outline the current recommendations for maternal group B streptococcus therapy.